SK Biopharmaceuticals Co., Ltd. (KRX:326030)
South Korea flag South Korea · Delayed Price · Currency is KRW
105,600
+500 (0.48%)
Mar 12, 2025, 9:00 AM KST

SK Biopharmaceuticals Revenue

SK Biopharmaceuticals had revenue of 136.60B KRW in the quarter ending September 30, 2024, with 51.21% growth. This brings the company's revenue in the last twelve months to 511.33B, up 75.77% year-over-year. In the year 2023, SK Biopharmaceuticals had annual revenue of 354.89B with 44.16% growth.

Revenue (ttm)
511.33B
Revenue Growth
+75.77%
P/S Ratio
16.16
Revenue / Employee
2.12B
Employees
241
Market Cap
8,262.05B

Revenue Chart

History

Fiscal Year End Revenue Change Growth
Dec 31, 2023354.89B108.71B44.16%
Dec 31, 2022246.18B-172.47B-41.20%
Dec 31, 2021418.64B392.65B1,510.23%
Dec 31, 202026.00B-97.85B-79.01%
Dec 31, 2019123.85B122.75B11,172.24%
Dec 31, 2018 Pro Pro Pro
Dec 31, 2017 Pro Pro Pro
Dec 31, 2016 Pro Pro Pro
Dec 31, 2015 Pro Pro Pro
Dec 31, 2014 Pro Pro Pro

Revenue Definition

Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.

Full Definition

Related Stocks

Company Name Revenue
Samsung Biologics 4,547.32B
Celltrion 2,876.25B
ALTEOGEN 74.38B
HLB Co., Ltd. 51.92B
Yuhan 2,008.84B
Sam Chun Dang Pharm. 208.22B
LigaChem Biosciences 101.42B
PharmaResearch 317.00B
Revenue Rankings